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ABSTRACT  
Background and Aims Identifying typologies of social determinants of health (SDoH) 
vulnerability influencing drug use practices among women living with HIV (WLWH) can help 
address associated harms. This research aimed to explore the association of SDoH clusters with 
drug use among WLWH.  Design Latent class analysis (LCA) was used to identify the distinct 
clusters of SDoH. Inverse probability weighting (IPW) was employed to account for 
confounding and potential selection bias. Associations were analyzed using generalized linear 
model with log link and Poisson distribution, and then weighted risk ratio (RR) and 95% 
confidence intervals (CI) were reported.  Setting, Participants Data from 1,422 WLWH 
recruited at time-point 1 of the Canadian HIV Women’s Sexual and Reproductive Health Cohort 
Study (CHIWOS, 2013-2015), with 1,252 participants at 18 months follow-up (time-point 2). 
Measurements Drug use was defined as use of illicit/non-prescribed opioids/stimulants in the 
past six months. SDoH indicators included: race discrimination, gender discrimination, HIV 
stigma, social support, access to care, food security, income level, employment status, education, 
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housing status, and histories of recent sex work and incarceration. Findings LCA identified four 
SDoH classes: no/least SDoH adversities (6.6%), discrimination/stigma (17.7%), economic 
hardship (30.8%), and most SDoH adversities (45.0%). Drug use was reported by 17.5% and 
17.2% at time-point 1 and 2, respectively. WLWH with no/least SDoH adversities were less 
likely to report drug use than those in economic hardship class (weighted RR = 0.13; 95% CIs= 
0.03, 0.63), discrimination/stigma class (weighted RR = 0.15; 95% CIs = 0.03, 0.78), and most 
SDoH adversities class (weighted RR = 0.13; 95% CIs = 0.03, 0.58). Conclusions Social 
determinants of health vulnerabilities are associated with greater likelihood of drug use, 
underscoring the significance of addressing interlinked social determinants and drug use through 
the course of HIV care and treatment. 
Keywords Drug use; social determinants; HIV; women; CHIWOS; Canada. 
  




Illicit drug use, particularly opioids and stimulants, is common among people living with HIV 
(PLWH). For example, 10%, 24%, and 39% of PLWH in a US study reported heroin, 
amphetamines, and cocaine use, respectively, by any administration route [1]. Although data on 
the prevalence of drug use among women living with HIV (WLWH) is limited, 28.6% of 
WLWH reported recent crack cocaine use, with 3.2% as persistent users [2]. In Canada, available 
evidence showed that 25.0% and 11.3% of WLWH reported recent crack cocaine and heroin use 
(by any route), respectively [3].  
Illicit drug use remains one of the most important factors influencing engagement in the 
HIV care cascade among individuals with HIV [1, 4-6]. Much evidence has documented poorer 
HIV treatment outcomes among people who use drugs, particularly among WLWH [5-11]. For 
example, greater suboptimal combination antiretroviral therapy (cART) adherence was 
documented among WLWH who reported a history of drug use than among women who did not, 
or among men regardless of drug use [7]. Drug use also predicts increased risk of disease 
progression, HIV transmission, and mortality [1, 2, 10], and continues to complicate HIV care 
and treatment efforts among PLWH [12, 13]. Although active drug use has been shown to 
complicate the clinical management of individuals with HIV and common comorbidities such as 
hepatitis C, increasing evidence documents how marginalization and criminalization of people 
who use/inject drugs interferes with access and adherence to HIV medications [14]. Particular 
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attention, therefore, needs to be given to such drug use practice throughout the course of HIV 
care and treatment among WLWH.  
Although some determinants of illicit drug use are well documented (e.g., demographics, 
cognitive, behavioral) [15], few studies have explored the role of the social determinants of 
health (SDoH). The SDoH are the conditions (e.g., economic and social marginalization, and 
various forms of discrimination) in which people are born, work, live, and age, and the wider set 
of forces shaping the conditions of daily life that greatly contribute to health inequalities [16]. 
Greater adversities regarding these living conditions can lead to high levels of physiological and 
psychological stresses arising from coping with stressors [16]. For PLWH, HIV-related stigma in 
intersection with other social determinants (e.g., race and gender discrimination)[17] can result 
in coping behaviors such as illicit drug use [18] to help contend with worries and stresses [19], 
which can in turn increase vulnerabilities to HIV-related health outcomes [18, 20-22].  
Notably, multiple dimensions of SDoH tend to co-occur, and may cluster together into 
common combinations. Such concomitant determinants have been consistently treated as 
independent when studied in association with drug use. For example, previous studies have 
assessed the separate association of HIV stigma [23], food insecurity [24], unemployment [25], 
and low social support [26] with drug use. However, there are limited data examining how 
clustering of these determinants is related to drug use. Such evidence is essential for developing 
HIV care and treatment programs to address potentially modifiable adversities and reduce their 
impacts on the lives of WLWH. Drawing on the Canadian HIV Women’s Sexual and 
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Reproductive Health Cohort Study (CHIWOS) [27], we conducted a latent class analysis (LCA) 
to uncover underlying clusters of SDoH. LCA as a data reduction strategy classifies individuals 
into mutually exclusive and exhaustive latent classes using multiple categorical observed 
variables [28]. LCA has been a useful technique for identifying population subgroups in different 
disciplines (e.g., substance using women at risk for HIV [29]. We then applied inverse 
probability weighting to address confounding and selection bias in examining the association of 




We used data from CHIWOS (www.chiwos.ca), a community-based cohort study. As previously 
described [27], CHIWOS is a large cohort of WLWH (≥16 years; trans inclusive) residing in the 
Canadian provinces of British Columbia (BC), Ontario, and Quebec. WLWH (n=1,422) were 
interviewed during 2013-2015 (time-point 1) and after ~18-months (time-point 2; n=1,252). We 
considered 170 participants (11.9%) lacking time-point 2 data as censored. Participants were 
recruited through peers, HIV clinics, AIDS service or community-based organizations, word of 
mouth, and other methods [30]. Trained Peer Research Associates (PRAs) administered the 
survey through in-person interviews at clinics, community sites, or participants’ homes, or via 
phone/Skype. Informed consent was obtained from all participants prior to the interview, 
This article is protected by copyright. All rights reserved.
7 
 
consistent with the ethics protocol approved by Simon Fraser University, University of British 
Columbia/Providence Health, Women’s College Hospital, and McGill University Health Centre. 
Drug use 
Recent drug use was defined as last three months at the first time-point and last six months at the 
second time-point, and included use of opioids (heroin, speedballs, Dilaudid, non-prescribed 
methadone, OxyContin/Oxycodone, morphine, Talwin & Ritalin) or stimulants (cocaine, crack, 
crystal methamphetamine, amphetamine, MDA). The regular (daily or at least once/week) or 
episodic (less than once/week) use of these drugs was ascertained among those who reported any 
use. Due to small proportions in the episodic use category (i.e., ~1%), a binary outcome at time-
point 2 was created: use of any vs. no drugs.  
SDoH indicators 
A set of potentially modifiable SDoH that have the potential to co-occur among WLWH were 
examined at time-point 1, including: racial discrimination, gender discrimination, enacted HIV 
stigma, perceived social support, barriers to access to care, food security, housing status, income 
level, employment status, education, recent sex work involvement, and recent incarceration. 
Included SDoH indicators: a) were measured at the first survey time-point, b) are potentially 
modifiable, c) were currently or recently experienced, and; d) align with the Canadian list of 
SDoH [19] (HIV-related stigma being an exception specific to PLWH). Selection of SDoH was 
limited to current or recent conditions to avoid the potential for collider stratification bias [31] 
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that could be introduced in a selected (HIV-positive) sample by studying earlier social 
determinants that may have affected HIV status. 
  Racial discrimination was measured with the 8-item Everyday Discrimination Scale 
(current study α=0.96) [32]. In line with operationalization used in the prior research [33], 
WLWH who reported discriminatory experiences due to their race (e.g., treated with less 
courtesy, respect) sometimes, frequently, or almost every day were considered as having 
experienced racial discrimination. The same scale (with the same definition) focusing on 
discriminatory mistreatments due to gender was used to measure gender discrimination (α=0.94). 
Enacted HIV stigma was measured using three items of Wright's abridged 10-item version of 
Berger's HIV Stigma Scale (α=0.85), measuring the extent to which WLWH experienced 
enacted/personalized stigma toward PLWH [34]. Experience of HIV-related stigma was defined 
if WLWH reported any HIV-related discriminatory events with strongly agree/agree response 
options (i.e., been hurt by people’s reaction, stopped socializing, or lost friends). Social support 
was examined by the 4-item Medical Outcome Study: Social Support Survey [35], measuring 
emotional-informational, tangible, affectionate, and positive social interaction supports (α=0.85). 
The overall mean score ranged 1-5, with > 2 indicating poor social support availability [36]. 
Difficulties in access to care was assessed using the 12-item Barriers to Access to Care Scale 
[37], measuring barriers experienced due to geography/distance, medical and psychological 
service, community stigma, and personal resource (α=0.93). The overall mean severity scores 
ranged 1-4, with ≥ 2 signifying severe/significant barriers [21]. Past-year experiences of food 
This article is protected by copyright. All rights reserved.
9 
 
security were examined by three items: fears of running out of food; experiences of running out 
of food; and unaffordability of balanced meals, yielding an overall score ranging 1-6, with > 1 
indicating food insecurity [38]. Income level was defined as low if participants reported having a 
yearly household income level < $20,000. Current employment status was categorized as 
unemployed (no income or income only from non-employment sources such as 
unemployment/welfare, dividends and interest, or pension) vs. employed (any paid job). Current 
education level was dichotomized as below high school vs. completed high school or more. 
Current housing status was also measured. Participants who reported residing in places such as a 
self-contained room, transition house, halfway house, safe house, or outdoors were considered as 
unstable housing. Past six months sex work involvement was also included, and defined as 
having been provided with money, drug, shelter, food, etc. in exchange for sex. Finally, any past 
year experience of incarceration was included as a structural-level determinant indicating social 
exclusion.  
Covariates 
The following covariates were hypothesized to be associated with either both SDoH clusters and 
drug use or only drug use: age (continuous); ethnoracial groups (white/Caucasian, 
African/Caribbean/Black, Indigenous, others); province (BC, Ontario, Quebec); city size (large, 
others); sexual orientation (heterosexual, LGBQ); relationship status (married/common-
law/relationship, others); years living with HIV (<6 years, 6-14 years, > 14 years); cART status 
(optimal [≥ 95% adherence], suboptimal [< 95% adherence], not engaged in HIV treatment); 
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ever diagnosed with a mental health condition; resilience (10-item Resilience Scale) [39]; any 
history of childhood sexual/physical violence; any experience of adulthood 
sexual/physical/verbal/action-limited violence; having been under the care of Child Protection 
Services or in foster care; and alcohol use (abstainers/low, moderate [1-7 drinks/week], heavy [> 
7 drinks/week]). Drug use history before or at time-point 1 was also included to account for 
confounding by outcome history [40]. Missing values of covariates under the assumption of 
missing at random were singly imputed to reduce the loss of statistical power when computing 
inverse probability weights (IPW) [41]. 
Latent class analysis (LCA) 
We used LCA to identify clusters of SDoH indicators. Under the assumption that latent classes 
are independent given the observed indicators, LCA aims to identify distinct groups of 
individuals with similar patterns within an unobserved categorical variable [28]. LCA was 
started with a two-class model and systematically increased to more classes (Table S1). LCA 
provides both class membership probabilities and item-response probabilities condition on class 
membership to help interpret the final identified class (Table 1). The expectation–maximization 
(EM) algorithm with 5,000 iterations was employed to identify the best model fit [42]. The 
selection of the best LCA model was informed by using goodness-of-fit indices, supporting 
statistics, and interpretability of class memberships. The following fit statistics were reported: 
log-likelihood, Akaike’s information criterion (AIC), Bayesian information criterion (BIC), and 
sample-size-adjusted BIC (aBIC), and consistent AIC (CAIC) [43-45]. Lower values of these 
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criteria indicate better fit and parsimony. Two supporting statistics were also reported: Entropy 
as  a measure of classification accuracy, with values approaching to 1 indicating better class 
separation [46], and the percentage of seeds associated with the fitting models, with values close 
to 100% indicating they were unlikely to have hit the local maxima. For each model, the log-
likelihood was replicated with 1,000 random starting values to avoid local maxima. Under the 
assumption of missing at random, LCA accounted for missing values of the SDoH indicators 
using the full information maximum likelihood estimation. LCA was conducted using SAS 
PROC LCA procedure [47]. 
Models and estimations  
We used inverse probability weights (IPW) [48, 49] to account for confounding due to the 
presence of potentially imbalanced covariates across the SDoH clusters, and inverse probability 
censoring weights (IPCW) to account for prospective selection bias due to potentially non-
random loss to follow-up/censoring (Table S2). The product of these two weights yielded the 
final stabilized weights (Table S3), producing a pseudo-population in which the independent 
variable and covariates are unassociated (Table S4) [48]. In fitting models through IPW, we 
assumed correct specification of IPW models, conditional exchangeability, consistency, and 
positivity [50].  
Control of confounding using IPW  
SDoH clusters were modeled using a multinomial logistic regression to estimate stabilized 
weights: the numerator was computed as the marginal probability of the SDoH clusters divided 
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by the denominator, which was computed as the probability that a participant was assigned to an 
SDoH cluster given the covariates and opioid/stimulant use history. These models were all 
performed among participants without censored information in time-point 2. 
Control of selection bias using IPCW  
Additionally, to account for any potential selection bias due to differential loss-to-follow-up at 
time-point 2, we estimated IPCW using logistic regression models: numerator was defined as the 
probability of not being censored given SDoH, and denominator was computed as the probability 
of not being censored given SDoH, covariates and opioid/stimulant use history [48].  
Association of SDoH clusters with drug use  
The association between SDoH clusters and any opioid/stimulant use was examined using 
generalized linear models with log link and Poisson distribution; crude and weighted risk ratios 
(RRs) and 95% confidence intervals (CIs) were reported. Further adjustment was made for 
imbalanced covariates after applying the IPW. These analyses were conducted using Stata 15.  
Sensitivity analysis 
We reported E-value to evaluate the extent to which residual (unmeasured) confounding might 
explain away the observed associations, and computed as: E = RR* + sqrt{RR* × RR* – 1}, 
where RR* = 1/RR for RR < 1 [51]. E-value is a representation of the minimum strength of 
association that an unmeasured confounder would need to have with SDoH clusters and drug use 
to nullify the observed associations.  
 




SDoH classes  
Prevalences for individual social determinants ranged from 6.3% (N = 82/1307) and 6.5% (N = 
92/1419) for recent sex work involvement and incarceration to 71.8% (N = 1004/1398) and 
77.8% (N = 1098/1412) for enacted HIV stigma and unemployment, respectively (Table 1). 
After considering LCA fit statistics and model interpretability, the four-class model was 
determined as the optimal number of classes (Table S1). These four classes included WLWH 
with either none/least SDoH adversities (class 1 labeled as no/least SDoH adversities: N = 94 
[6.6%]); WLWH who predominantly reported experiencing race and gender discrimination along 
with HIV-related stigma and barriers in access to care, but without economic hardship indicators 
(class 2 labelled as discrimination/stigma: N = 256 [18.0%]); WLWH who mainly reported food 
insecurity, low household income, and unemployment, accompanied with HIV-related stigma 
(class 3 labeled as economic hardship: N = 430 [30.2%]); and WLWH who experienced gender 
and race discrimination, HIV-related stigma, low social support, access to care difficulties, food 
insecurity, low income, and unemployment (class 4 labeled as most SDoH adversities: N = 642 
[45.2%]). 
Participants’ characteristics  
WLWH were an average of 42.8 [SD 10.6] years of age, with 584 (41.1%) members of the white 
ethnoracial group, 1237 (87.3%) heterosexual, 689 (48.5%) single, 552 (40.2%) living with HIV 
This article is protected by copyright. All rights reserved.
14 
 
for 6-14 years, 863 (70.0%) self-reporting optimal cART adherence; 819 (62.7%) and 1057 
(80.4%) reported exposure to violence as children and adults, respectively, 573 (40.7%) reported 
a mental health diagnosis, and 140 (10.1%) were heavy alcohol users. The distributions of these 
covariates across the SDoH clusters are presented in Table 2.  
SDoH clusters and drug use  
Overall, opioid/ stimulant use at time-points 1 and 2 were respectively reported by 244 (17.5%) 
and 212 (17.2%.). Drug use at time-point 2 was reported by 143 (26.4%) among WLWH with 
most SDoH adversities, with 53 (14.1%), 13 (5.6%) and 3 (3.5%) for economic hardship, 
discrimination/stigma, and no/least SDoH classes, respectively (Figure 1). The crude regression 
analysis demonstrated that WLWH in the no/least SDoH adversities, discrimination/stigma, and 
economic hardship classes had significantly lower likelihood of opioid/stimulant use than 
WLWH in the most SDoH adversities class. Compared with the most SDoH adversities class, 
weighted analysis showed that WLWH in no/least SDoH class were at 87% decreased risk of 
drug use (RR 0.13, 95% CI: 0.03, 0.58), while an association was not observed for other classes. 
Additionally, WLWH in the no/least SDoH class were at decreased risk of drug use compared to 
WLWH in the economic hardship class (RR 0.13, 95% CI: 0.03, 0.63) and discrimination/stigma 
class (RR 0.15; 95% CI: 0.03, 0.78) (Table 3). 
The sensitivity analysis suggested that these associations were relatively robust to 
potential unmeasured confounding. For instance, for the observed RR: 0.13 for drug use among 
those with no/least SDoH adversities versus those with most adversities, an unmeasured 
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confounder correlated with both exposure and outcome by RRs of ~14.86-fold each, above and 
beyond the measured confounders, would explain away the observed association, but weaker 
confounding would not. Such an E-value for the upper 95% limit of the same association was 
2.84-fold (Table 3).  
 
DISCUSSION  
In our study of data from a large prospective cohort of WLWH in Canada, we observed that most 
WLWH reported experiencing multiple forms of a set of mutually reinforcing SDoH. We 
identified two partially overlapped SDoH clusters of discrimination/stigma and economic 
hardship as well as one cluster containing most of the SDoH adversities. Most notably, we found 
that the prevalence of self-reported opioid/stimulant use was approximately seven times higher in 
WLWH who experienced the most SDoH adversities than those experiencing no/least adversity 
(26.4% vs. 3.5%). WLWH with no/least adversity were substantially less likely to report drug 
use at ~18 months follow up compared with WLWH experiencing an accumulation of social 
disadvantages. 
Overall, the high prevalence of socio-structural adversities among WLWH is consistent 
with existing knowledge that women experience substantial SDoH vulnerabilities and multiple 
forms of these adversities [52, 53]. The majority of the SDoH indicators were well-distinguished 
across the SDoH classes using LCA analysis, except for low education, unstable housing, sex 
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work involvement, and incarceration. That these four determinants were less distinctive may be 
due to their relatively low proportions, likely resulted in a low overall impact on drug use in the 
current sample of WLWH. 
We documented that the clustered classes of multiple SDoH adversities were associated 
with drug use. Notably, no difference was observed in the risk of drug use for the two classes of 
discriminations/stigma and economic hardship compared with the class with most SDoH 
adversities and also the same risk of drug use was estimated when WLWH in the no/least class 
were compared with WLWH in these two classes. Such findings may help shed light on the 
processes that generate and reinforce well-documented syndemics of HIV and substance use, by 
showing the role that each specific cluster of SDoH may play in initiation/continuation of drug 
use. Our results suggest that improving modifiable social determinants may be crucial to 
addressing this syndemic [54]. Harm reduction and treatment interventions need to seriously 
consider the important role of multiple SDoH – regardless of their types. Drug treatment 
programs that mainly focus on behavior change interventions may result in limited impact if no 
additional efforts are made to change the social environments of drug users [55]. 
 Our findings may also have implication for HIV care and treatment programs by 
illuminating the association of current social determinants with illicit drug use, which has been 
shown to create challenges within the HIV care cascade. Prior evidence has demonstrated how 
income level [56], HIV stigma [22], and food insecurity [57] increase vulnerabilities to 
suboptimal cART adherence by limiting access to HIV care and treatment services, and affecting 
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individuals’ health seeking behaviors. Illicit drug use, e.g., crack cocaine, also impacts HIV 
clinical care through the same mechanism of HIV treatment interruptions [2, 10, 11, 58]. 
Individually or combined, these factors can threaten the benefits accompanied with early HIV 
treatment initiation and the commitments toward eliminating the HIV pandemic. Paying 
particular attention to these interlinked social and drug use determinants should be a key priority 
in efforts to improve HIV medical care for WLWH, and merits continued and thorough 
investigation. Given the impacts of these SDoH adversities and risk practices on HIV care and 
treatment outcomes, these findings indicate a need for regular assessment of these factors and 
targeted support for women with greater needs within routine HIV care [59], which if addressed 
holistically, may reduce the likelihood of suboptimal HIV clinical outcomes. 
 While this study took advantage of CHIWOS as the largest community-based research 
cohort of WLWH in Canada, it had some limitations. First, non-random sampling of the 
participants may limit the generalizability and interpretation of our findings. Second, we relied 
on self-reported drug use, which may be subject to social desirability bias; however, participants 
were interviewed by PRAs who also experienced living with HIV (and in some cases, using 
drugs), and this may have limited such bias. Third, although unmeasured confounding is a source 
of bias in observational research, our sensitivity analysis showed that relatively strong 
unmeasured confounding would be required to nullify the observed associations.  
 The current research has several strengths despite these limitations: First, we used data 
from a nationwide large sample of WLWH. Second, our research extends the relatively limited 
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extant knowledge on drug use among women with HIV. Third, our research contributes to 
theoretical development through examining the inclusion of detailed individual-level data of 
current and modifiable social determinants as leading stressors in the target population’s daily 
life. Fourth, we demonstrated how these determinants cluster together using LCA, a probability-
based technique that provides a better insight into the underlying clusters of the individual SDoH 
indicators given the concurrent occurrence of these determinants. Fifth, IPW was used to account 
for both confounding and selection bias. Finally, the survey had a high retention rate (88%) after 
18 months of follow-up.  
 Despite a growing body of evidence on the independent associations between social 
determinants and drug use, less focus has been put on ways these determinants overlap, or on 
their clustering impacts on drug use. The complex relationships between the SDoH indicators, 
the documented (individual) associations with barriers to care, and stigma that surrounds both 
drug use and many aspects of social adversity suggest that HIV care programs will need to make 
intentional efforts to ensure that patients have full access to optimal care across the HIV care 
cascade. Our findings support the targeted assessment of multiple social determinant and drug 
use vulnerabilities; HIV-specific and women-centered care models have good potential to create 
the kind of low-stigma environment that would allow for these issues to be both assessed and 
addressed [60]. Developing evidence-based treatment for drug dependence, including harm 
reduction strategies, requires a recognition of the role of social determinants of health. 
Individuals with these socio-structural adversities in intersection with drug use may continue to 
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experience greater challenges with regard to HIV treatment adherence and HIV outcomes; 
therefore, the continued support for individuals with greater vulnerabilities is required. 
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Table 1 Class Membership Probabilities and Item-Response Probabilities of Social Determinants 




SDoH measures  
 None/least 
SDoH 
(N = 94; 
6.6%)b 
Discrimination 
and Stigma  








(N = 642; 
45.2%) 
Race discrimination  
(708/1408; 50.3%)a 
No 0.00 0.40c 0.91 0.18 
Yes 0.00 0.60 0.09 0.82 
Noned 1.00 0.00 0.00 0.00 
Gender discrimination  
(818/1415; 57.1%) 
No 0.00 0.33 0.91 0.04 
Yes 0.00 0.67 0.09 0.96 
None 1.00 0.00 0.00 0.00 
Enacted HIV stigma  
(1004/1398; 71.8%) 
No 0.00 0.22 0.40 0.17 
Yes 0.00 0.78 0.60 0.83 
None 1.00 0.00 0.00 0.00 
Low social support  
(722/1367; 52.8%) 
No 0.00 0.51 0.51 0.37 
Yes 0.00 0.49 0.49 0.63 
None 1.00 0.00 0.00 0.00 
High barriers to access to 
care  
No 0.00 0.43 0.55 0.36 
Yes 0.00 0.57 0.45 0.64 
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(725/1371; 52.8%) None 1.00 0.00 0.00 0.00 
Food insecurity   
(907/1416; 64.1%) 
No 0.00 0.63 0.31 0.18 
Yes 0.00 0.37 0.69 0.82 
None 1.00 0.00 0.00 0.00 
Low income  
(901/1379; 65.3%) 
No 0.00 0.90 0.21 0.11 
Yes 0.00 0.10 0.79 0.89 
None 1.00 0.00 0.00 0.00 
Unemployment  
(1098/1412; 77.8%) 
No 0.00 0.67 0.09 0.02 
Yes 0.00 0.33 0.91 0.98 
None 1.00 0.00 0.00 0.00 
Low education  
(227/1415; 16.0%) 
No 0.00 1.00 0.83 0.75 
Yes 0.00 0.00 0.17 0.25 
None 1.00 0.00 0.00 0.00 
Unstably housed  
(152/1422; 10.7%) 
No 0.00 0.99 0.90 0.83 
Yes 0.00 0.01 0.10 0.17 
None 1.00 0.00 0.00 0.00 
Recent sex work practice  
(82/1307; 6.3%) 
No 0.00 0.99 0.95 0.90 
Yes 0.00 0.01 0.05 0.10 
None 1.00 0.00 0.00 0.00 
Recent incarceration  No 0.00 1.00 0.96 0.88 
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(92/1419; 6.5%) Yes 0.00 0.00 0.04 0.12 
None 1.00 0.00 0.00 0.00 
a (n/N; %) indicating the prevalence of the SDoH indicators under the study; b Class membership 
probabilities; c Item-response probabilities, indicating the probability of experiencing a SDoH 
indicator for each identified latent class; d We categorized each SDoH measure into three 
categories: No: indicating either did not have/experience this determinant, Yes: indicating either 
living/experiencing this determinant, None: indicating either did not experience any of these 12 
determinants or experienced only one (i.e., least). Item response probabilities of “Yes” category 
≥ 0.50 are bolded, and item response probabilities of “None” category with 100% are underlined. 
The “None” category was added to produce a distinct class named “None/leased SDoH 
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Table 2 Characteristics of Women Living with HIV (WLWH) across the Social Determinants of Health (SDoH) Classes– CHIWOS 
Time-point 1, 2013-2015 (N = 1,422). 
 
Variables 










Age, yrd (mean [SD]) 42.8 [10.6] 39.2 [10.3]  43.5 [10.6] 42.9 [11.5] 43.1 [10.0] 0.007 
Ethno-racial group      <0.001 
White/Caucasian 584 (41.1)a 58 (61.7) 97 (37.9) 219 (50.9) 210 (32.7)  
African/Caribbean/Black 418 (29.4) 23 (24.5) 109 (42.6) 123 (28.6) 163 (25.4)  
Indigenous 318 (22.3) 7 (7.4) 29 (11.3) 60 (14.0) 222 (34.6)  
Other 102 (7.2) 6 (6.4) 21 (8.2) 28 (6.5) 47 (7.3)  
Province      <0.001 
Ontario  717 (50.4) 50 (53.2) 131 (51.2) 235 (54.6) 301 (46.9)  
British Columbia  356 (25.0) 13 (13.8) 49 (19.1) 65 (15.1) 229 (35.7)  
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Quebec   349 (24.6) 31 (33.0) 76 (29.7) 130 (30.2) 112 (17.5)  
Living in large cities 1169 (82.2) 83 (88.3) 203 (79.3) 345 (80.2) 538 (83.8) 0.106 
Bing heterosexual 1237 (87.3) 85 (90.4) 237 (93.3) 395  (91.9) 520 (81.4) <0.001 
Relationship status      <0.001 
Single (non-married) 689 (48.5) 40 (42.6) 100 (39.1) 201 (46.7) 348 (54.4)  
Married/common-law  454 (32.0) 44 (46.8) 103 (40.2) 134 (31.1) 173 (27.0)  
Others  277 (19.5) 10 (10.6) 53 (20.7) 95 (22.1) 119 (18.6)  
Years living with HIV       0.001 
< 6 years 345 (25.1) 23 (25.0) 40 (15.7) 128 (31.4) 154 (24.8)  
6-14 years  552 (40.2) 35 (38.0) 118 (46.7) 140 (34.3) 259 (41.8)  
> 14 years  477 (34.7) 34 (37.0) 96 (37.8) 140 (34.3) 207 (33.4)  
Taking HIV treatment      0.001 
Yes, optimal (≥ 95%) 863 (70.0) 65 (69.9) 163 (64.7) 279 (65.0) 356 (55.5)  
Yes, suboptimal (< 95%) 312 (22.0) 12 (12.9) 52 (21.4) 74 (17.2) 172 (26.8)  
Not engaged in treatment  240 (17.0) 16 (17.2) 35 (13.9) 76 (17.7) 113 (17.6)  
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Mental health diagnosis 573 (40.7) 26 (28.0) 93 (36.6) 134 (31.6) 320 (50.3) <0.001 
Resiliency (below median)c 662 (47.1) 22 (23.66) 104 (40.9) 172 (40.6) 364 (57.4) <0.001 
Childhood violence 819 (62.7) 34 (38.6) 138 (56.8) 211 (53.8) 436 (74.7) <0.001 
Adulthood violence 1057 (80.4) 52 (59.1) 189 (77.5) 284 (71.9) 532 (90.5) <0.001 
Child development events 326 (23.0) 10 (10.6) 33 (13.0) 74 (17.3) 209 (32.7) <0.001 
Heavy alcohol use       0.132 
Abstainers/low (< 1 drink/week) 956 (69.1) 64 (68.8) 174 (68.5) 302 (71.1) 419 (68.1)  
Moderate (1-7 drinks/week) 288 (20.8) 22 (23.7) 60 (23.6) 88 (20.7) 118 (19.2)  
Heavy (> 7 drinks/week) 140 (10.1) 7 (7.5) 20 (7.9) 35 (8.2) 78 (12.7)  
Drug use historyd        
Before study entry 234 (16.8) 3 (3.2) 10 (3.9) 48 (11.24) 173 (27.5) <0.001 
At entry (time-point 1) 244 (17.5) 2 (2.2) 11 (4.3) 50 (11.9) 181 (28.8) <0.001 
a Data are presented as N (%) unless specified; b P-values are for the chi-square test for categorical covariates and one-way ANOVA 
for continuous covariates; c Scores ranged 10-70, with higher scores indicating increased resilience (median = 64); d Opioid/stimulant 
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use histories before and at time-point 1.   
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Table 3 Inverse Probability Weighted Estimates of the Association of the Social Determinants of Health (SDoH) Classes with Drug 









P-value Weighted RR 
(95% CI) 
P-value Weighted RR  Upper CI  
Economic hardship class vs.   
 Most SDoH adversities 
0.53  
(0.40, 0.71) 




Discrimination/stigma class vs.  
 Most SDoH adversities 
0.21  
(0.12, 0.37) 




None/least adversities class vs.  
 Most SDoH adversities  
0.13 (0.04, 
0.40) 
<0.001 0.13  
(0.03, 0.58)   
0.008 
14.86 2.84 
Discrimination/stigma class vs.  
 Economic hardship  
0.40  
(0.22, 0.71) 
0.002 0.87  
(0.44, 1.68)  
0.678 
--- --- 
None/least adversities class vs.  0.24  0.015 0.13  0.011 14.86 2.55 
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 Economic hardship  (0.07, 0.76) (0.03, 0.63) 
None/least adversities class vs.  
 Discrimination/stigma  
0.61  
(0.18, 2.1) 




a N = 1,236 in crude analysis and N= 1,225 in weighted analysis; b RR: risk ratio (95% confidence intervals: CI); c This is a sensitivity 
analysis evaluating the extant to which an unmeasured confounder would explain away the exposure-outcome estimates observed for 
the association between the SDoH classes and drug use. E-value was check for the observed point estimate and the upper 95% CI that 
is close to the null RR = 1.  
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Figure 1 Prevalence of Drug Usea According to the Social Determinants of Health (SDoH) 
Classes Obtained from the Latent Class Analysis (LCA) – CHIWOSb. 
 
a Stimulants: cocaine, crack (crack cocaine), crystal, speed (amphetamine) and MDA; Opioids: 
heroin, speedballs (heroin+ cocaine), Dilaudid (hydromorphone), non-prescription use of 
methadone, OxyContin/Oxycodone, morphine, Talwins & Ritalin. These drugs were measured at 
baseline (time-point 1, 2013-15) and in ~18 month follow up (time-point 2; 2015-17); b Analytic 
sample size for these prevalences was 1,395 at time-point1 and 1,236 at time-point 2.   
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Supplementary tables   
Table S1 Comparison of Goodness-of-fit Measures for Different Class Models (N=1,422) 
Model  LLa AICb BICc CAICd Entropy % seedse 
1-class  -12363.0 10080.9 10207.2 10231.2 1.000 100% 
2-class  -8582.2 2569.1 2826.9 2875.9 1.000 100% 
3-class  -8271.3 1997.4 2386.7 2460.7 0.843 98.4% 
4-classf -8030.0 1564.9 2085.6 2184.6 0.831 93.5% 
5-class  -7966.5 1487.8 2140.0 2264.0 0.819 35.0% 
6-class  -7922.1 1449.0 2232.7 2381.7 0.814 15.0% 
7-class  -7889.8 1434.5 2349.7 2523.7 0.745 32.4% 
a Log-Likelihood (LL); b Akaike information criterion (AIC); c Bayesian information criterion 
(BIC); d Consistent AIC (CAIC), e Percentage of seeds associated with best fitted model (% 
seeds); f 4-class model had the lowest BIC and CAIC. Moving forward to model with more 
classes, entropy suggested lower classification accuracy (e.g., ~10% reduction from 4-class to 7-
class). In addition, the 4-class model had a higher percentage of seeds associated with best fitted 
model (i.e., increased confidence that the best solution was achieved even though it is not a fit 
criterion). Fit indices/statistics align with model interpretability suggested the 4-class model 
provided a better fit with plausible distribution of the sample within each class. 
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Table S2 Characteristics of Women Living with HIV (WLWH) Who Were Lost to Follow-up 
(i.e., censored), CHIWOS, 2013-2017  
 
Variables  
Not Lost to follow up 
(N = 1252) 
Lost to follow up 
(N = 170) 
P-value 
SDoH classes    0.057 
Class 1: No/least SDoH adversities  88 (7.03) 6 (3.53)  
Class 2: Discrimination/Stigma  232 (18.53) 24 (14.12)  
Class 3: Economic adversities   381 (30.43) 49 (28.82)  
Class 4: Most SDoH adversities  551 (44.01) 91 (53.53)  
Age, yrd (mean [SD]) 42.9 [10.61] 42.2 [10.34] 0.430 
Ethno-racial group   0.062 
White/Caucasian 515 (41.13) 69 (40.59)  
African/Caribbean/Black 380 (30.35) 38 (22.35)  
Indigenous 272 (21.73) 46 (27.06)  
Other 85 (6.79) 17 (10.00)  
Province   0.018 
Ontario  637 (50.88) 80 (47.06)  
British Columbia  299 (23.88) 57 (33.53)  
Quebec   316 (25.24) 33 (19.41)  
Living in large cities 1029 (82.19) 140 (82.35) 0.958 
heterosexual 1095 (87.81) 142 (83.53) 0.116 
Relationship status   0.596 
Single (non-married) 612 (48.92) 77 (45.56)  
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Married/common-law  394 (31.49) 60 (35.50)  
Others  245 (19.58) 32 (18.93)  
Years living with HIV    0.648 
< 6 years 310 (25.49) 35 (22.15)  
6-14 years  487 (40.05) 65 (41.14)  
> 14 years  419 (34.46) 58 (36.71)  
Taking HIV treatment   0.012 
Yes, optimal (≥ 95%) 759 (60.91) 104 (61.54)  
Yes, suboptimal (< 95%) 264 (21.19) 48 (28.40)  
Not engaged in treatment  223 (17.90) 17 (10.06)  
Mental health diagnosis 499 (40.21) 74 (44.58) 0.282 
Resiliency (below median) 568 (45.81) 94 (56.97) 0.007 
Childhood violence 708 (61.51) 111 (71.15) 0.019 
Adulthood violence 918 (79.07) 139 (90.26) 0.001 
Child development events 269 (21.55) 57 (33.73) <0.001 
Heavy alcohol use    0.011 
Abstainers/low (< 1 drink/week) 865 (70.44) 94 (59.12)  
Moderate (1-7 drinks/week) 242 (19.71) 46 (28.93)  
Heavy (> 7 drinks/week) 121 (9.85) 19 (11.95)  
Stimulant/opioid use     
Before study entry 187 (15.19) 47 (28.31) <0.001 
At entry (time-point 1) 193 (15.70) 51 (30.72) <0.001 
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Table S3 Distributions of the Estimated Weights for the Classes of the Social Determinants of 
Health (SDoH), Censoring, and Both, CHIWOS, time-point 1, 2013-2015 
 Mean (SD) Percentiles 
5th 25th 50th 75th 95th 
Stabilized weights for 
SDoH weights  
      
 Class 1 0.90 (1.30) 0.16 0.26 0.46 0.95 3.21 
 Class 2 0.96 (0.82) 0.39 0.54 0.74 1.04 2.20 
 Class 3 1.00 (0.67) 0.50 0.63 0.80 1.12 2.26 
 Class 4 0.99 (0.60) 0.48 0.60 0.81 1.18 2.01 
 Overall  0.98 (0.73) 0.43 0.58 0.78 1.13 2.18 
Stabilized weights for  
censoring weights  
      
 Overall  0.99 (0.08) 0.91 0.94 0.98 1.02 1.14 
Stabilized weights for 
final weights  
      
 Class 1 0.89 (1.38) 0.15 0.26 0.45 0.93 3.18 
 Class 2 0.97 (0.86) 0.39 0.53 0.73 1.02 2.30 
 Class 3 1.02 (0.75) 0.47 0.62 0.78 1.13 2.35 
 Class 4 0.97 (0.55) 0.50 0.62 0.81 1.15 1.89 
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Table S4 Inverse-Probability Weighted Estimates of the Parameters of a Marginal Structural 
Model for the Association of the Classes of the Social Determinants of Health (SDoH) on Drug 
Use among Women Living with HIV (WLWH), CHIWOS, Canada, 2013-2017  
 SDoH classesa  





adversities   
Age, yr (mean) 0.99 (0.95, 1.02)  0.99 (0.97, 1.01) 1.00 (0.98, 1.01) 
Ethno-racial groups    
White/Caucasian 1 1 1 
Indigenous 1.01 (0.29, 3.46) 0.91 (0.5, 1.66) 0.88 (0.56, 1.38) 
African/Caribbean/Black 0.75 (0.36, 1.56) 0.87 (0.57, 1.32) 0.96 (0.67, 1.38) 
Other 0.58 (0.18, 1.85) 0.98 (0.48, 1.99) 0.99 (0.53, 1.86) 
Study province    
Ontario  1 1 1 
British Columbia  0.61 (0.21, 1.78) 0.63 (0.39, 1.02) 1.05 (0.69, 1.59) 
Quebec  0.77 (0.35, 1.67) 0.90 (0.56, 1.45) 1.00 (0.69, 1.43) 
Living large size cities 1.08 (0.42, 2.74) 1.11 (0.70, 1.76) 0.96 (0.63, 1.48) 
Heterosexual 0.60 (0.14, 2.56) 1.65 (0.86, 3.14) 1.22 (0.76, 1.95) 
Relationship status    
Single (non-married) 1 1 1 
Married 0.84 (0.38, 1.85) 0.81 (0.53, 1.25) 1.07 (0.74, 1.56) 
Others  0.89 (0.31, 2.55) 0.78 (0.49, 1.26) 1.02 (0.68, 1.53) 
Years living with HIV    
< 6 years 1 1 1 
6-14 years  1.22 (0.49, 3.05) 0.88 (0.52, 1.49) 0.91 (0.62, 1.34) 
> 14 years  1.53 (0.68, 3.48) 0.89 (0.52, 1.52) 0.95 (0.63, 1.41) 
Taking HIV treatment    
This article is protected by copyright. All rights reserved.
Yes, optimal 1 1 1 
Yes, suboptimal 0.57 (0.23, 1.42) 1.11 (0.66, 1.87) 1.02 (0.67, 1.55) 
Not in treatment  0.75 (0.32, 1.78) 0.97 (0.55, 1.70) 0.89 (0.59, 1.36) 
Mental health diagnosis 1.44 (0.66, 3.18) 0.82 (0.55, 1.23) 0.94 (0.68, 1.31) 
Resiliency (below median) 0.48 (0.22, 1.03) 0.90 (0.6, 1.34) 0.97 (0.71, 1.34) 
Childhood violence 1.02 (0.51, 2.03) 0.89 (0.59, 1.34) 0.95 (0.69, 1.32) 
Adulthood violence 0.71 (0.33, 1.53) 0.90 (0.55, 1.45) 0.92 (0.62, 1.37) 
Childhood development events 0.67 (0.22, 2.02) 0.98 (0.56, 1.70) 0.96 (0.63, 1.45) 
Heavy alcohol use     
Abstainers/low (< 1 drink/week) 1 1 1 
Moderate (1-7 drinks/week) 1.55 (0.55, 4.34) 0.98 (0.62, 1.57) 0.87 (0.58, 1.30) 
Heavy (> 7 drinks/week) 0.30 (0.12, 0.79)b 1.68 (0.79, 3.55) 0.97 (0.57, 1.67) 
Stimulant/opioid use     
Before study entry 0.95 (0.17, 5.38) 0.84 (0.37, 1.90) 0.88 (0.55, 1.41) 
At entry (time-point 1)  0.89 (0.16, 5.06) 0.72 (0.32, 1.58) 0.95 (0.61, 1.50) 
a Base class in multinomial logistic regression was most SDoH adversities; b Further adjustment 
for this imbalanced covariate resulted in no changes in the regression estimates presented in 
Table 3. 
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